Source disclosure: February 04, 2026
M3,Inc. [2413.T]
TOKYO, Feb 04 (Pulse News Wire) – M3,Inc. (2413.T) reported robust revenue growth of 29% percent year-over-year for the first nine months of fiscal 2025, driven by stable performance across its segments.
Operating profit reached ¥62.30 billion, up from ¥53.00 billion in the same period last year. Additionally, the sale of approximately ¥4 billion worth of related company shares contributed positively to earnings. In detail, the Medical Platform segment saw sales increase by 20% percent, while Evidence Solutions recorded a modest rise of 2%. Career Solutions experienced a significant boost of 11% percent, largely due to increased revenues from pharmacist-focused services.
Site Solutions showed a decline in profitability despite higher sales, attributed to the initial costs of setting up new facilities. Looking ahead, M3,Inc. continues to focus on expanding its global footprint and enhancing operational efficiency through digital transformation initiatives. The company plans to maintain its aggressive investment strategy, including mergers and acquisitions, to capitalize on existing and emerging markets.
AI-translated content. 🟢 Confidence: High See terms • Original filing